Differential levels of α-synuclein, β-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease
Differential levels of α-synuclein, β-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease
复制标题
DOI：
10.1136/jnnp.2009.197483
复制
发表时间：
2010-06-01
影响因子：
11
通讯作者：
Ikeuchi, Takeshi
中科院分区：
文献类型：
--
作者：
Kasuga, Kensaku;Tokutake, Takayoshi;Ikeuchi, Takeshi
背景路易体痴呆（DLB）的临床诊断是基于共识标准，但该标准的敏感性相对较低。没有普遍接受的生物标志物来区分DLB与其他痴呆症。方法86例DLB、Alzheimer病（AD）和其他痴呆患者分为3组，DLB组34例，AD组31例，其他痴呆组21例。还检查了2例α-突触核蛋白基因（SNCA）重复的患者。使用ELISA试剂盒定量A β和tau。结果AD患者脑脊液中总tau蛋白和磷酸化tau蛋白水平以及A β 40/42和tau/A β 42比值均显著高于DLB患者（P
Background The clinical diagnosis of dementia with Lewy bodies (DLB) is made on the basis of consensus criteria; however, the sensitivity of the criteria is relatively low. There are no generally accepted biomarkers to distinguish DLB from other dementias. Here the utility of quantification of a-synuclein, beta-amyloid42 (A beta 42) and tau in the CSF of patients with DLB, Alzheimer's disease (AD) and other dementias was examined.Methods 86 patients were divided into three age and sex matched groups: DLB (n=34), AD (n=31) and other dementias (n=21). Two patients with alpha-synuclein gene (SNCA) duplication were also examined. A beta and tau were quantified using an ELISA kit. A modified sandwich ELISA was developed which enables the sensitive quantification of CSF alpha-synuclein.Results Total and phosphorylated tau levels as well as A beta 40/42 and tau/A beta 42 ratios were significantly higher in AD patients than in patients with DLB (p